PainReform (NASDAQ:PRFX) Trading Down 1.3% – Here’s Why

PainReform Ltd. (NASDAQ:PRFX) dropped 1.3% during mid-day trading on Monday . The stock traded as low as $0.87 and last traded at $0.8838. Approximately 96,867 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 695,639 shares. The stock had previously closed at $0.8955.

Analyst Ratings Changes

PRFX has been the subject of a number of research reports. Wall Street Zen raised shares of PainReform from a “strong sell” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

PainReform Stock Down 1.3%

The stock’s 50-day moving average price is $1.27 and its 200 day moving average price is $1.52. The firm has a market capitalization of $1.78 million, a price-to-earnings ratio of -0.01 and a beta of 0.61.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.